Alberto Albanese

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5202537/alberto-albanese-publications-by-year.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68 22,128 142 334 h-index g-index citations papers 6.2 365 6.3 24,944 L-index avg, IF ext. papers ext. citations

#	Paper	IF	Citations
334	Development of a patient journey map for people living with cervical dystonia <i>Orphanet Journal of Rare Diseases</i> , 2022 , 17, 130	4.2	1
333	Trigeminal features in COVID-19 patients with smell impairment. <i>International Forum of Allergy and Rhinology</i> , 2021 , 11, 1253-1255	6.3	3
332	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2021 , 20, 182-192	24.1	29
331	Worldwide barriers to genetic testing for movement disorders. <i>European Journal of Neurology</i> , 2021 , 28, 1901-1909	6	2
330	Functional motor phenotypes: to lump or to split?. <i>Journal of Neurology</i> , 2021 , 268, 4737-4743	5.5	13
329	Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet Europe. <i>Frontiers in Neurology</i> , 2021 , 12, 646841	4.1	2
328	Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site. <i>Parkinsonism and Related Disorders</i> , 2021 , 87, 70-74	3.6	1
327	Neurological features in SARS-CoV-2-infected patients with smell and taste disorder. <i>Journal of Neurology</i> , 2021 , 268, 1570-1572	5.5	16
326	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic" neurology. <i>European Journal of Neurology</i> , 2021 , 28, 1752-1758	6	14
325	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. <i>Parkinsonism and Related Disorders</i> , 2021 , 82, 146-149	3.6	4
324	Neuroimaging in idiopathic adult-onset focal dystonia. <i>Neurological Sciences</i> , 2021 , 42, 2947-2950	3.5	1
323	Impulse control behavior in GBA-mutated parkinsonian patients. <i>Journal of the Neurological Sciences</i> , 2021 , 421, 117291	3.2	2
322	Sudden Onset, Fixed Dystonia and Acute Peripheral Trauma as Diagnostic Clues for Functional Dystonia. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1107-1111	2.2	O
321	Functional gait disorders: Demographic and clinical correlations. <i>Parkinsonism and Related Disorders</i> , 2021 , 91, 32-36	3.6	2
320	Design and Operation of the Lombardy Parkinson's Disease Network. <i>Frontiers in Neurology</i> , 2020 , 11, 573	4.1	3
319	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. <i>Parkinsonism and Related Disorders</i> , 2020 , 71, 40-43	3.6	10
318	Dystonia and Tremor: The Clinical Syndromes with Isolated Tremor. <i>Tremor and Other Hyperkinetic Movements</i> , 2020 , 6, 319	2	23

Patient-centred management of Parkinson's disease. Lancet Neurology, The, 2020, 19, 888-889 317 24.1 Coronary embolization from aortic valve fibroelastoma. Clinical Case Reports (discontinued), 2020, 8, 1610-96122 316 GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian 315 7 35 Cohort. Movement Disorders, 2020, 35, 2106-2111 Idiopathic Non-task-Specific Upper Limb Dystonia, a Neglected Form of Dystonia. Movement 314 13 Disorders, 2020, 35, 2038-2045 Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. Movement Disorders 2.2 313 20 Clinical Practice, 2020, 7, 920-929 Clinical Reasoning: A case of COVID-19-associated pharyngeal-cervical-brachial variant of 312 6.5 11 Guillain-Barr syndrome. Neurology, 2020, 95, 978-983 Demographic and clinical determinants of neck pain in idiopathic cervical dystonia. Journal of 311 11 4.3 Neural Transmission, **2020**, 127, 1435-1439 Motor and Sensory Features of Cervical Dystonia Subtypes: Data From the Italian Dystonia Registry. 310 4.1 Frontiers in Neurology, 2020, 11, 906 Parkinsonism and dysautonomia: Multiple system atrophy?. Parkinsonism and Related Disorders, 3.6 1 309 **2020**, 77, 146-149 Implementation of the Current Dystonia Classification from 2013 to 2018. Movement Disorders 308 2.2 Clinical Practice, 2019, 6, 250-253 Dystonia: diagnosis and management. European Journal of Neurology, 2019, 26, 5-17 6 307 37 306 Amyotrophic onset in GCH1 dopa-responsive dystonia. *Iranian Journal of Neurology*, **2019**, 18, 181-183 o.6 Adult diagnosis of Cockayne syndrome. Neurology, 2019, 93, 854-855 6.5 O 305 VPS35-Based Approach: A Potential Innovative Treatment in Parkinson's Disease. Frontiers in 304 4.1 Neurology, 2019, 10, 1272 Management of cervical dystonia with botulinum neurotoxins and EMG/ultrasound guidance. 303 1.7 21 Neurology: Clinical Practice, 2019, 9, 64-73 Expert recommendations for diagnosing cervical, oromandibular, and limb dystonia. Neurological 302 27 3.5 Sciences, 2019, 40, 89-95 Quality and reporting of guidelines on the diagnosis and management of dystonia. European 6 301 9 Journal of Neurology, 2018, 25, 275-283 Treatable inherited rare movement disorders. Movement Disorders, 2018, 33, 21-35 300 57

299	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. Parkinsonism and Related Disorders, 2018 , 56, 33-40	3.6	14
298	Recent developments in clinical trials of botulinum neurotoxins. <i>Toxicon</i> , 2018 , 147, 77-83	2.8	11
297	Management algorithm for BoNT injections with electromyography and ultrasound guidance in cervical dystonia. <i>Toxicon</i> , 2018 , 156, S14-S15	2.8	
296	Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 3588-3597	6.9	19
295	Prefrontal Cortical Stimulation in Tourette Disorder: Proof-of-concept Clinical and Neuroimaging Study. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 499-505	2.2	2
294	The Italian Dystonia Registry: rationale, design and preliminary findings. <i>Neurological Sciences</i> , 2017 , 38, 819-825	3.5	22
293	Efficacy of pallidal stimulation in isolated dystonia: a systematic review and meta-analysis. <i>European Journal of Neurology</i> , 2017 , 24, 552-560	6	97
292	Shifting from constant-voltage to constant-current in Parkinson's disease patients with chronic stimulation. <i>Neurological Sciences</i> , 2017 , 38, 1505-1508	3.5	7
291	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology, The</i> , 2017 , 16, 701-711	24.1	161
290	Failure of pallidal deep brain stimulation in DYT12-ATP1A3 dystonia. <i>Parkinsonism and Related Disorders</i> , 2017 , 45, 99-100	3.6	13
289	Cognitive decline in Huntington's disease expansion gene carriers. <i>Cortex</i> , 2017 , 95, 51-62	3.8	31
288	How Many Dystonias? Clinical Evidence. <i>Frontiers in Neurology</i> , 2017 , 8, 18	4.1	14
287	Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. <i>Frontiers in Neurology</i> , 2017 , 8, 35	4.1	43
286	A genome-wide association study in multiple system atrophy. <i>Neurology</i> , 2016 , 87, 1591-1598	6.5	104
285	Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review. <i>Parkinsonism and Related Disorders</i> , 2016 , 32, 108-115	3.6	15
284	Quantitative gait analysis in parkin disease: Possible role of dystonia. <i>Movement Disorders</i> , 2016 , 31, 17	72 9 -172	2817
283	A 52-Year-Old Man with Myoclonic Jerks. <i>Brain Pathology</i> , 2016 , 26, 291-2	6	1
282	Clinical guidelines: No more mistaken identities for botulinum neurotoxins. <i>Nature Reviews Neurology</i> , 2016 , 12, 373-4	15	6

(2014-2016)

281	Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2016 , 23, 45-52	6	119
280	Dystonia and Tremor: The Clinical Syndromes with Isolated Tremor. <i>Tremor and Other Hyperkinetic Movements</i> , 2016 , 6, 319	2	15
279	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. <i>European Journal of Neurology</i> , 2016 , 23, 772-9	6	5
278	"Complex" dystonia is not a category in the new 2013 consensus classification. <i>Movement Disorders</i> , 2016 , 31, 1758-1759	7	4
277	Mitochondrial dysfunction in Parkinson disease: evidence in mutant PARK2 fibroblasts. <i>Frontiers in Genetics</i> , 2015 , 6, 78	4.5	45
276	Tics and Tremors 2015 , 743-750		
275	Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. <i>Neurology</i> , 2015 , 84, 1669-72	6.5	31
274	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. <i>Journal of Neurology</i> , 2015 , 262, 2201-13	5.5	42
273	Subthalamic involvement in monetary reward and its dysfunction in parkinsonian gamblers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 355-8	5.5	7
272	Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 562-4	5.5	58
271	Reliability and validity of the range of motion scale (ROMS) in patients with abnormal postures. <i>Pain Medicine</i> , 2015 , 16, 488-93	2.8	3
270	Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials. <i>Toxicon</i> , 2015 , 107, 89-97	2.8	9
269	Pallidal stimulation for acquired dystonia due to cerebral palsy: beyond 5 years. <i>European Journal of Neurology</i> , 2015 , 22, 426-e32	6	45
268	Reply to Dr Michaud et´al. <i>European Journal of Neurology</i> , 2015 , 22, e78	6	
267	Therapeutic advances in dystonia. <i>Movement Disorders</i> , 2015 , 30, 1547-56	7	18
266	Searching for the second best graft for coronary artery bypass surgery: a network meta-analysis of randomized controlled trials: European Journal of Cardio-thoracic Surgery, 2015, 47, 59-65; discussion 65	3	98
265	Neuropsychiatric Disturbances in Dystonia. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2015 , 171-199		1
264	Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: from the advanced phase towards the late stage of the disease?. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 376-81	3.6	113

263	Designing clinical trials for dystonia. <i>Neurotherapeutics</i> , 2014 , 11, 117-27	6.4	14
262	Early DEtection of wEaring off in Parkinson disease: the DEEP study. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 204-11	3.6	90
261	Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. <i>Neurological Sciences</i> , 2014 , 35, 753-8	3.5	45
260	Isolated limb dystonia as presenting feature of Parkin disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 827-8	5.5	16
259	Deep brain stimulation for cervical dystonia. <i>Lancet Neurology, The</i> , 2014 , 13, 856-7	24.1	5
258	Minimally invasive direct coronary artery bypass improves late survival compared with drug-eluting stents in isolated proximal left anterior descending artery disease: a 10-year follow-up, single-center, propensity score analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014 , 148, 1310	1.5 6-22	31
257	Smoking cessation before coronary artery bypass grafting improves operative outcomes. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014 , 148, 468-74	1.5	15
256	Genome-wide association study in musician's dystonia: a risk variant at the arylsulfatase G locus?. <i>Movement Disorders</i> , 2014 , 29, 921-7	7	35
255	Reply: dystonia after severe head injuries. <i>Movement Disorders</i> , 2014 , 29, 578-9	7	O
254	The New Classification System for the Dystonias: Why Was it Needed and How was it Developed?. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 280-284	2.2	28
253	Clinical Use of Botulinum Neurotoxin: Neuromuscular Disorders 2014 , 51-93		1
252	Validation of the Italian version of the Movement Disorder SocietyUnified Parkinson's Disease Rating Scale. <i>Neurological Sciences</i> , 2013 , 34, 683-7	3.5	85
251	Dystonia rating scales: critique and recommendations. <i>Movement Disorders</i> , 2013 , 28, 874-83	7	103
250	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. <i>Journal of Neurology</i> , 2013 , 260, 2701-14	5.5	102
249	Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. <i>Journal of Neurology</i> , 2013 , 260, 714-40	5.5	52
248	Alpha-synuclein gene duplication: marked intrafamilial variability in two novel pedigrees. <i>Movement Disorders</i> , 2013 , 28, 813-7	7	22
247	Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. <i>Toxicon</i> , 2013 , 67, 94-114	2.8	171
246	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology, The</i> , 2013 , 12, 264-74	24.1	322

(2012-2013)

245	Suicidal ideation in a European Huntington's disease population. <i>Journal of Affective Disorders</i> , 2013 , 151, 248-58	6.6	59
244	Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. <i>Toxicon</i> , 2013 , 67, 115-28	2.8	89
243	Phenomenology and classification of dystonia: a consensus update. <i>Movement Disorders</i> , 2013 , 28, 863-	-7 , 3	1217
242	Pathological gambling in Parkinson's disease: subthalamic oscillations during economics decisions. <i>Movement Disorders</i> , 2013 , 28, 1644-52	7	38
241	Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease: ITALY. <i>Neurology: Clinical Practice</i> , 2013 , 3, 476-477	1.7	Ο
240	Dystonic Tremor 2013 , 203-218		1
239	Ambiguous idiom processing in Parkinson's disease patients. Cognitive Neuropsychology, 2013, 30, 495-	5063	5
238	Attentional Networks in Parkinson Disease. Behavioural Neurology, 2013 , 27, 495-500	3	7
237	Attentional networks in Parkinson's disease. <i>Behavioural Neurology</i> , 2013 , 27, 495-500	3	1
236	Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. <i>Lancet Neurology, The</i> , 2012 , 11, 429-42	24.1	277
236		3.2	277 38
	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in		
235	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. <i>Neuropsychologia</i> , 2012 , 50, 1980-9 Epidural premotor cortical stimulation in primary focal dystonia: clinical and 18F-fluoro	3.2	38
235	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. <i>Neuropsychologia</i> , 2012 , 50, 1980-9 Epidural premotor cortical stimulation in primary focal dystonia: clinical and 18F-fluoro deoxyglucose positron emission tomography open study. <i>Movement Disorders</i> , 2012 , 27, 533-8 Clinical management of pain and fatigue in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> ,	3.2	38
235 234 233	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. <i>Neuropsychologia</i> , 2012 , 50, 1980-9 Epidural premotor cortical stimulation in primary focal dystonia: clinical and 18F-fluoro deoxyglucose positron emission tomography open study. <i>Movement Disorders</i> , 2012 , 27, 533-8 Clinical management of pain and fatigue in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012 , 18 Suppl 1, S233-6 Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation	3.2 7 3.6	38 22 22
235 234 233 232	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. <i>Neuropsychologia</i> , 2012 , 50, 1980-9 Epidural premotor cortical stimulation in primary focal dystonia: clinical and 18F-fluoro deoxyglucose positron emission tomography open study. <i>Movement Disorders</i> , 2012 , 27, 533-8 Clinical management of pain and fatigue in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012 , 18 Suppl 1, S233-6 Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation (DBS) for severe neurological diseases. <i>Neurological Sciences</i> , 2012 , 33, 1285-303 Relationships between disability, quality of life and prevalence of nonmotor symptoms in	3.2 7 3.6 3.5	38 22 22 25
235 234 233 232 231	Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. <i>Neuropsychologia</i> , 2012 , 50, 1980-9 Epidural premotor cortical stimulation in primary focal dystonia: clinical and 18F-fluoro deoxyglucose positron emission tomography open study. <i>Movement Disorders</i> , 2012 , 27, 533-8 Clinical management of pain and fatigue in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012 , 18 Suppl 1, S233-6 Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation (DBS) for severe neurological diseases. <i>Neurological Sciences</i> , 2012 , 33, 1285-303 Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 35-9 Cortical myoclonus in childhood and juvenile onset Huntington's disease. <i>Parkinsonism and Related</i>	3.2 7 3.6 3.5 3.6	38 22 22 25 31

227 Inherited Myoclonus Syndromes **2012**, 207-220

226	Pathophysiology and Molecular Pathology of Dystonia and Tics 2012 , 15-25		
225	Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease. <i>Neurological Sciences</i> , 2012 , 33, 847-53	3.5	8
224	Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation. <i>European Journal of Neurology</i> , 2012 , 19, 76-83	6	21
223	Update on dystonia. <i>Current Opinion in Neurology</i> , 2012 , 25, 483-90	7.1	23
222	Discrepancies in reporting the CAG repeat lengths for Huntington's disease. <i>European Journal of Human Genetics</i> , 2012 , 20, 20-6	5.3	16
221	Nanotechnology and vascular neurosurgery: an in vivo experimental study on microvessels repair using laser photoactivation of a nanostructured hyaluronan solder. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2012 , 26, 447-56	0.7	1
220	Conflict-dependent dynamic of subthalamic nucleus oscillations during moral decisions. <i>Social Neuroscience</i> , 2011 , 6, 243-56	2	50
219	Diagnostic issues in childhood and adult dystonia. Expert Opinion on Medical Diagnostics, 2011, 5, 483-50	00	1
218	Terminology for preparations of botulinum neurotoxins: what a difference a name makes. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 89-90	27.4	51
217	Choice-option evaluation is preserved in early Huntington and Parkinson's disease. <i>NeuroReport</i> , 2011 , 22, 753-7	1.7	9
216	Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). <i>Archives of Neurology</i> , 2011 , 68, 223-30		73
215	Deep brain stimulation for Parkinson's disease: where do we stand?. Frontiers in Neurology, 2011, 2, 33	4.1	6
214	EFNS guidelines on diagnosis and treatment of primary dystonias. <i>European Journal of Neurology</i> , 2011 , 18, 5-18	6	277
213	Behavioral and personality features in patients with lateralized Parkinson's disease. <i>European Journal of Neurology</i> , 2011 , 18, 772-7	6	9
212	Response to letter by Dr Neil Murray. <i>European Journal of Neurology</i> , 2011 , 18, e62-e62	6	
211	Cell therapy for Parkinson's disease: have the glory days gone?. <i>Lancet Neurology, The</i> , 2011 , 10, 492-3	24.1	3
210	Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. <i>Lancet Neurology, The</i> , 2011 , 10, 1074-85	24.1	144

(2010-2011)

209	Deep brain stimulation for movement disorders. Considerations on 276 consecutive patients. Journal of Neural Transmission, 2011 , 118, 1497-510	4.3	34
208	Pre-operative evaluations for DBS in dystonia. <i>Movement Disorders</i> , 2011 , 26 Suppl 1, S17-22	7	14
207	Inclusion and exclusion criteria for DBS in dystonia. <i>Movement Disorders</i> , 2011 , 26 Suppl 1, S5-16	7	48
206	In vivo evidence for GABA(A) receptor changes in the sensorimotor system in primary dystonia. <i>Movement Disorders</i> , 2011 , 26, 852-7	7	45
205	Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: need for long-term clinical trials. <i>Movement Disorders</i> , 2011 , 26, 1370; author reply 1371	7	2
204	Impact of nonmotor symptoms on disability in patients with Parkinson's disease. <i>International Journal of Rehabilitation Research</i> , 2011 , 34, 316-20	1.8	11
203	Disability and profiles of functioning of patients with Parkinson's disease described with ICF classification. <i>International Journal of Rehabilitation Research</i> , 2011 , 34, 141-50	1.8	36
202	Primary focal hyperhidrosis in a new family not linked to known loci. <i>Dermatology</i> , 2011 , 223, 335-42	4.4	9
201	Abnormal tactile temporal discrimination in psychogenic dystonia. <i>Neurology</i> , 2011 , 77, 1191-7	6.5	50
200	NMDA receptor gene variations as modifiers in Huntington disease: a replication study. <i>PLOS Currents</i> , 2011 , 3, RRN1247		18
199	Functioning and disability in Parkinson's disease. <i>Disability and Rehabilitation</i> , 2010 , 32 Suppl 1, S33-41	2.4	17
198	Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. <i>Brain</i> , 2010 , 133, 2664-76	11.2	295
197	Emerging parkinsonian phenotypes. <i>Revue Neurologique</i> , 2010 , 166, 834-40	3	3
196	Low-voltage bilateral pallidal stimulation for severe meige syndrome in a patient with primary segmental dystonia: case report. <i>Operative Neurosurgery</i> , 2010 , 67, onsE308; discussion onsE308	1.6	10
195	Transient gender-related effects in Parkinson's disease patients with subthalamic stimulation. Journal of Neurology, 2010 , 257, 603-8	5.5	19
194	Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports. <i>Journal of Neurology</i> , 2010 , 257, S298-304	5.5	25
193	Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 578-86	7	319
192	The diagnostic challenge of primary dystonia: evidence from misdiagnosis. <i>Movement Disorders</i> , 2010 , 25, 1619-26	7	45

191	Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010 , 25, 2604-12	7	155
190	Distinguishing scan without evidence of dopaminergic depletion patients with asymmetric resting tremor from Parkinson's disease: a clinical diagnosis of dystonia is required. <i>Movement Disorders</i> , 2010 , 25, 2899	7	8
189	Differential diagnosis of dystonia. European Journal of Neurology, 2010, 17 Suppl 1, 1-8	6	15
188	Cutaneous herpes zoster and implantable pulse generator. <i>Neuromodulation</i> , 2010 , 13, 99-101	3.1	1
187	Advances in the genetics of primary torsion dystonia. F1000 Biology Reports, 2010, 2,		5
186	Botulinum Neurotoxin in Tremors, Tics, Hemifacial Spasm, Spasmodic Dysphonia, and Stuttering 2009 , 112-130		1
185	Clinical Trials of Botulinum Toxin in Adult Spasticity 2009 , 148-158		
184	White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study. <i>American Journal of Neuroradiology</i> , 2009 , 30, 1222-6	4.4	184
183	Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation. <i>Movement Disorders</i> , 2009 , 24, 557-63	7	60
182	Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. <i>Movement Disorders</i> , 2009 , 24, 801-12	7	83
181	Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1154-61	7	114
180	Is this dystonia?. Movement Disorders, 2009, 24, 1725-31	7	57
179	Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. <i>Movement Disorders</i> , 2009 , 24, 2350	-77	32
178	Mutation screening of the DYT6/THAP1 gene in Italy. <i>Movement Disorders</i> , 2009 , 24, 2424-7	7	36
177	Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. <i>Neurotoxicity Research</i> , 2009 , 15, 224-31	4.3	50
176	Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. <i>European Journal of Neurology</i> , 2009 , 16, 392-8	6	33
175	Unique properties of botulinum toxins. <i>Toxicon</i> , 2009 , 54, 675	2.8	3
174	Botulinum toxin for the management of adult patients with upper motor neuron syndrome. <i>Toxicon</i> , 2009 , 54, 634-8	2.8	16

173	Discussion of unique properties of botulinum toxins. <i>Toxicon</i> , 2009 , 54, 702-8	2.8	5
172	Impaired body movement representation in DYT1 mutation carriers. <i>Clinical Neurophysiology</i> , 2008 , 119, 1864-1869	4.3	19
171	Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. <i>Archives of Neurology</i> , 2008 , 65, 1191-4		186
170	Rivastigmine in Parkinson's disease dementia. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 1181-8	4.3	6
169	Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. <i>Journal of Neurology</i> , 2008 , 255, 1372-7	5.5	28
168	Levodopa-induced dyskinesias and their management. <i>Journal of Neurology</i> , 2008 , 255 Suppl 4, 32-41	5.5	53
167	Mood disorder following DBS of the left amygdaloid region in a dystonia patient with a dislodged electrode. <i>Movement Disorders</i> , 2008 , 23, 147-50	7	22
166	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008 , 23, 1093-9	7	168
165	A neurophysiological study of myoclonus in patients with DYT11 myoclonus-dystonia syndrome. <i>Movement Disorders</i> , 2008 , 23, 2041-8	7	32
164	PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008 , 29, 565	4.7	58
163	Results by motor cortex stimulation in treatment of focal dystonia, Parkinson's disease and post-ictal spasticity. The experience of the Italian Study Group of the Italian Neurosurgical Society. <i>Acta Neurochirurgica Supplementum</i> , 2008 , 101, 13-21	1.7	32
162	Normal cardiovascular reflex testing in patients with parkin disease. <i>Movement Disorders</i> , 2007 , 22, 528	- 3 2	8
161	Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. <i>European Journal of Neurology</i> , 2007 , 14, 66-72	6	33
160	Spontaneous neuronal activity of the posterior hypothalamus in trigeminal autonomic cephalalgias. <i>Neurological Sciences</i> , 2007 , 28, 93-5	3.5	29
159	Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 248-52	5.5	102
158	Can falls be prevented in Parkinson's disease?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 661	5.5	3
157	Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. <i>Neurology</i> , 2007 , 68, 875-6	6.5	37
156	Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. <i>Neurology</i> , 2007 , 69, 1062-3; author reply 1063	6.5	5

155	Dystonia: clinical approach. Parkinsonism and Related Disorders, 2007, 13 Suppl 3, S356-61	3.6	11
154	Clinical Features of Dystonia and European Guidelines for Diagnosis and Treatment 2007 , 3-9		O
153	Management of bladder, prostatic and pelvic floor disorders. <i>Neurotoxicity Research</i> , 2006 , 9, 161-72	4.3	8
152	Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006 , 21, 809-15	7	83
151	Analysis of blink rate in patients with blepharospasm. <i>Movement Disorders</i> , 2006 , 21, 1225-9	7	37
150	Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 1232-5	7	18
149	Non-DYT1 early-onset primary torsion dystonia: comparison with DYT1 phenotype and review of the literature. <i>Movement Disorders</i> , 2006 , 21, 1411-8	7	32
148	Synergistic control of protein kinase Cgamma activity by ionotropic and metabotropic glutamate receptor inputs in hippocampal neurons. <i>Journal of Neuroscience</i> , 2006 , 26, 3404-11	6.6	57
147	Onset and progression of primary torsion dystonia in sporadic and familial cases. <i>European Journal of Neurology</i> , 2006 , 13, 1083-8	6	14
146	A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. <i>European Journal of Neurology</i> , 2006 , 13, 433-4	46	234
146 145	A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. <i>European Journal of Neurology</i> , 2006 , 13, 433-4 Safety and efficacy of botulinum toxin type A following long-term use. <i>European Journal of Neurology</i> , 2006 , 13 Suppl 4, 35-40	4 ⁶	234
	plus syndromes: report of an EFNS/MDS-ES Task Force. <i>European Journal of Neurology</i> , 2006 , 13, 433-4 Safety and efficacy of botulinum toxin type A following long-term use. <i>European Journal of</i>		
145	plus syndromes: report of an EFNS/MDS-ES Task Force. <i>European Journal of Neurology</i> , 2006 , 13, 433-4 Safety and efficacy of botulinum toxin type A following long-term use. <i>European Journal of Neurology</i> , 2006 , 13 Suppl 4, 35-40 The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration.	6	125
145	plus syndromes: report of an EFNS/MDS-ES Task Force. <i>European Journal of Neurology</i> , 2006 , 13, 433-4 Safety and efficacy of botulinum toxin type A following long-term use. <i>European Journal of Neurology</i> , 2006 , 13 Suppl 4, 35-40 The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. <i>Neurology</i> , 2005 , 64, 1810-2 Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians.	6.5	125 111
145 144 143	plus syndromes: report of an EFNS/MDS-ES Task Force. European Journal of Neurology, 2006, 13, 433-4 Safety and efficacy of botulinum toxin type A following long-term use. European Journal of Neurology, 2006, 13 Suppl 4, 35-40 The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology, 2005, 64, 1810-2 Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. European Journal of Human Genetics, 2005, 13, 748-52 Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated	6.5	125 111 169
145 144 143	Safety and efficacy of botulinum toxin type A following long-term use. European Journal of Neurology, 2006, 13, 433-4 Safety and efficacy of botulinum toxin type A following long-term use. European Journal of Neurology, 2006, 13 Suppl 4, 35-40 The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology, 2005, 64, 1810-2 Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. European Journal of Human Genetics, 2005, 13, 748-52 Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegeneration. Movement Disorders, 2005, 20, 208-12 High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. Journal of	6 6.5 5.3	125 111 169 34
145 144 143 142 141	Safety and efficacy of botulinum toxin type A following long-term use. European Journal of Neurology, 2006, 13, 433-4 Safety and efficacy of botulinum toxin type A following long-term use. European Journal of Neurology, 2006, 13 Suppl 4, 35-40 The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology, 2005, 64, 1810-2 Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. European Journal of Human Genetics, 2005, 13, 748-52 Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegeneration. Movement Disorders, 2005, 20, 208-12 High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. Journal of Neurology, 2005, 252, 208-11 The European Multiple System Atrophy-Study Group (EMSA-SG). Journal of Neural Transmission,	6 6.5 5.3 7 5.5	125 111 169 34 32

(2003-2005)

137	Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. <i>Brain</i> , 2005 , 128, 2240-9	11.2	837
136	Botulinum neurotoxin to treat chronic anal fissure: results of a randomized "Botox vs. Dysport" controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19, 695-701	6.1	53
135	Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene. <i>Annals of Neurology</i> , 2004 , 55, 448	9.4	28
134	PINK1 mutations are associated with sporadic early-onset parkinsonism. <i>Annals of Neurology</i> , 2004 , 56, 336-41	9.4	397
133	Phenotypic characterization of DYT13 primary torsion dystonia. <i>Movement Disorders</i> , 2004 , 19, 200-6	7	30
132	Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. <i>Movement Disorders</i> , 2004 , 19 Suppl 8, S146-56	7	21
131	Levodopa in the treatment of Parkinson's disease: current controversies. <i>Movement Disorders</i> , 2004 , 19, 997-1005	7	291
130	Hereditary early-onset Parkinson's disease caused by mutations in PINK1. <i>Science</i> , 2004 , 304, 1158-60	33.3	2586
129	Rivastigmine for dementia associated with Parkinson's disease. <i>New England Journal of Medicine</i> , 2004 , 351, 2509-18	59.2	919
128	Clinical presentation and progression of sporadic and familial primary torsion dystonia in Italy. <i>Advances in Neurology</i> , 2004 , 94, 171-8		4
128		0.7	54
	Advances in Neurology, 2004, 94, 171-8 Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A.	0.7	
127	Advances in Neurology, 2004, 94, 171-8 Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. American Journal of Gastroenterology, 2003, 98, 1439-40 A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the	0.7	54
127 126	Advances in Neurology, 2004, 94, 171-8 Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. American Journal of Gastroenterology, 2003, 98, 1439-40 A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the tau protein gene. Archives of Neurology, 2003, 60, 1454-6 Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin.	,	54 26
127 126 125	Advances in Neurology, 2004, 94, 171-8 Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. American Journal of Gastroenterology, 2003, 98, 1439-40 A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the tau protein gene. Archives of Neurology, 2003, 60, 1454-6 Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin. Current Medicinal Chemistry, 2003, 10, 603-23	4-3	542617
127 126 125	Advances in Neurology, 2004, 94, 171-8 Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. American Journal of Gastroenterology, 2003, 98, 1439-40 A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the tau protein gene. Archives of Neurology, 2003, 60, 1454-6 Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin. Current Medicinal Chemistry, 2003, 10, 603-23 The clinical expression of primary dystonia. Journal of Neurology, 2003, 250, 1145-51 A study of arm movements in Huntington's disease under visually controlled and blindfolded	4-3	54261758
127 126 125 124	Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. American Journal of Gastroenterology, 2003, 98, 1439-40 A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the tau protein gene. Archives of Neurology, 2003, 60, 1454-6 Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin. Current Medicinal Chemistry, 2003, 10, 603-23 The clinical expression of primary dystonia. Journal of Neurology, 2003, 250, 1145-51 A study of arm movements in Huntington's disease under visually controlled and blindfolded conditions. Neurological Sciences, 2003, 23, 287-93	4·3 5·5	5426175813

119	Abnormal gating of somatosensory inputs in essential tremor. Clinical Neurophysiology, 2003, 114, 120-	94.3	25
118	Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. <i>Urology</i> , 2003 , 62, 259-64; discussion 264-5	1.6	181
117	Role of the dopamine D5 receptor (DRD5) as a susceptibility gene for cervical dystonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 665-6	5.5	22
116	Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003 , 74, 175-82	5.5	152
115	Dystonia in parkinsonian syndromes. <i>Advances in Neurology</i> , 2003 , 91, 351-60		3
114	Review: several drugs are efficacious for symptomatic treatment of Parkinson disease. <i>ACP Journal Club</i> , 2003 , 138, 14		
113	Bilateral high frequency subthalamic stimulation in Parkinson's disease: long-term neurological follow-up. <i>Journal of Neurosurgical Sciences</i> , 2003 , 47, 119-28	1.3	31
112	Review: Several drugs are efficacious for symptomatic treatment of Parkinson disease. <i>ACP Journal Club</i> , 2003 , 138, 14		
111	Gabapentin improved sensory and motor symptoms in the restless legs syndrome. <i>ACP Journal Club</i> , 2003 , 139, 17		4
110	Park6-linked parkinsonism occurs in several european families. <i>Annals of Neurology</i> , 2002 , 51, 14-18	9.4	81
109	Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. <i>Annals of Neurology</i> , 2002 , 52, 849-53	9.4	179
108	Phenotypic variability of DYT1-PTD: does the clinical spectrum include psychogenic dystonia?. <i>Movement Disorders</i> , 2002 , 17, 1058-63	7	29
107	Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. <i>Movement Disorders</i> , 2002 , 17, 1371-4	7	228
106	Cognitive and psychiatric characterization of patients with Huntington's disease and their at-risk relatives. <i>Neurological Sciences</i> , 2002 , 23 Suppl 2, S105-6	3.5	16
105	PARK6 is a common cause of familial parkinsonism. <i>Neurological Sciences</i> , 2002 , 23 Suppl 2, S117-8	3.5	27
104	Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease. <i>Neurology</i> , 2002 , 58, 154	4 6. 50	153
103	Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. <i>Surgery</i> , 2002 , 131, 179-84	3.6	129
102	Initial bromocriptine did not change mortality in early, mild Parkinson disease. <i>Annals of Internal Medicine</i> , 2002 , 136, 109	8	1

101	Non-motor effects of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: preliminary physiological results. <i>Neurological Sciences</i> , 2001 , 22, 85-6	3.5	36
100	Identification of a novel primary torsion dystonia locus (DYT13) on chromosome 1p36 in an Italian family with cranial-cervical or upper limb onset. <i>Neurological Sciences</i> , 2001 , 22, 95-6	3.5	15
99	The current status and use of botulinum toxins. European Journal of Neurology, 2001, 8, 3-7	6	2
98	Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. <i>Movement Disorders</i> , 2001 , 16, 999-1006	7	57
97	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. <i>Movement Disorders</i> , 2001 , 16, 197-201	7	90
96	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13B6.32 in an Italian family with cranial-cervical or upper limb onset. <i>Annals of Neurology</i> , 2001 , 49, 362-366	9.4	90
95	Anterior rectocele due to obstructed defecation relieved by botulinum toxin. Surgery, 2001, 129, 524-9	3.6	27
94	Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. <i>American Journal of Human Genetics</i> , 2001 , 68, 895-900	11	389
93	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13B6.32 in an Italian family with cranial-cervical or upper limb onset 2001 , 49, 362		3
92	DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.1336.32 in an Italian family with cranial-cervical or upper limb onset. <i>Annals of Neurology</i> , 2001 , 49, 362-6	9.4	12
91	Botulinum toxin injected in the gastric wall reduces body weight and food intake in rats. <i>Alimentary Pharmacology and Therapeutics</i> , 2000 , 14, 829-34	6.1	41
90	Phenotype variability of dystonia in monozygotic twins. <i>Journal of Neurology</i> , 2000 , 247, 148-50	5.5	10
89	Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. <i>Diseases of the Colon and Rectum</i> , 2000 , 43, 376-80	3.1	59
88	Acute challenge with apomorphine and levodopa in Parkinsonism. <i>European Neurology</i> , 2000 , 43, 95-10	1 _{2.1}	50
87	Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. <i>American Journal of Surgery</i> , 2000 , 179, 46-50	2.7	109
86	The impact of deep brain stimulation on executive function in Parkinson's disease. <i>Brain</i> , 2000 , 123 (Pt 6), 1142-54	11.2	376
85	Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 613-9	5.5	49
84	Primary torsion dystonia: the search for genes is not over. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 67, 395-7	5.5	37

83	Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. <i>Journal of Neurosurgery</i> , 1999 , 91, 313-21	3.2	83
82	A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. <i>New England Journal of Medicine</i> , 1999 , 341, 65-9	59.2	317
81	Apomorphine and levodopa challenge in patients with a focal midbrain lesion. <i>Movement Disorders</i> , 1999 , 14, 269-75	7	3
80	Italian family with cranial cervical dystonia: clinical and genetic study. <i>Movement Disorders</i> , 1999 , 14, 820-5	7	22
79	Levodopa in the treatment of Parkinson's disease: a consensus meeting. <i>Movement Disorders</i> , 1999 , 14, 911-3	7	78
78	Consensus statement on the diagnosis of multiple system atrophy. <i>Journal of the Neurological Sciences</i> , 1999 , 163, 94-8	3.2	1006
77	Surgical treatment of Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 1999 , 167, 1-10	3.2	46
76	Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. <i>Neurology</i> , 1999 , 53, 85-90	6.5	290
75	Botulinum toxin in motor disorders. <i>Current Opinion in Neurology</i> , 1999 , 12, 447-56	7.1	9
74	Clinical genetic study of familial Parkinson's disease in Italy. <i>Advances in Neurology</i> , 1999 , 80, 181-6		3
73	New delivery systems for antiparkinsonian drugs. Advances in Neurology, 1999, 80, 549-54		
72	Long-term ventralis intermedius thalamic stimulation for parkinsonian tremor. Italian Registry for Neuromodulation in Movement Disorders. <i>Advances in Neurology</i> , 1999 , 80, 631-4		13
71	The current model of basal ganglia organization: a clinician's view. <i>Movement Disorders</i> , 1998 , 13, 980-1	7	2
70	Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. <i>Clinical Autonomic Research</i> , 1998 , 8, 359-62	4.3	248
69	Relief by botulinum toxin of voiding dysfunction due to prostatitis. <i>Lancet, The</i> , 1998 , 352, 625	40	39
68	Possible risk factors for primary adult onset dystonia: a case-control investigation by the Italian Movement Disorders Study Group. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998 , 64, 25-32	5.5	81
67	A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. <i>New England Journal of Medicine</i> , 1998 , 338, 217-20	59.2	305
66	Botulinum toxin injections in the internal anal sphincter for the treatment of chronic anal fissure: long-term results after two different dosage regimens. <i>Annals of Surgery</i> , 1998 , 228, 664-9	7.8	111

65	Consensus statement on the diagnosis of multiple system atrophy. <i>Journal of the Autonomic Nervous System</i> , 1998 , 74, 189-92		132
64	Non-DYT1 dystonia in a large Italian family. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 62, 357-60	5.5	30
63	Obsessive-compulsive behaviour and cognitive impairment in a parkinsonian patient after left putaminal lesion. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 62, 288-9	5.5	20
62	Emerging treatments in Parkinson's disease. <i>European Neurology</i> , 1997 , 38, 175-83	2.1	5
61	Zolpidem in Parkinson's disease. <i>Lancet, The</i> , 1997 , 349, 1222-3	40	99
60	Severe constipation in Parkinson's disease relieved by botulinum toxin. <i>Movement Disorders</i> , 1997 , 12, 764-6	7	67
59	Analysis of blink rate patterns in normal subjects. <i>Movement Disorders</i> , 1997 , 12, 1028-34	7	315
58	Functional impairment of nigrostriatal neurons progresses following withdrawal of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <i>Neuroscience</i> , 1996 , 75, 1185-91	3.9	2
57	Tardive lingual dystonia treated with clozapine. <i>Movement Disorders</i> , 1996 , 11, 585-6	7	19
56	Severe barbiturate withdrawal syndrome in migrainous patients. <i>Headache</i> , 1996 , 36, 119-21	4.2	18
55	Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996 , 60, 693-4	5.5	40
54	The clinical diagnosis of multiple system atrophy presenting as pure parkinsonism. <i>Advances in Neurology</i> , 1996 , 69, 393-8		4
53	Review article: the use of botulinum toxin in the alimentary tract. <i>Alimentary Pharmacology and Therapeutics</i> , 1995 , 9, 599-604	6.1	36
52	Clozapine in Huntington's disease. <i>Neurology</i> , 1995 , 45, 1023-4	6.5	16
51	Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995 , 59, 144-51	5.5	53
50	Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. <i>Archives of Neurology</i> , 1995 , 52, 294-8		145
49	Boxer disqualified for taking selegiline. <i>Lancet, The</i> , 1995 , 346, 647	40	3
48	Acute challenge with apomorphine in Huntington's disease: a double-blind study. <i>Clinical Neuropharmacology</i> , 1995 , 18, 427-34	1.4	15

47	Genetically determined cholinergic deficiency in the forebrain of C57BL/6 mice. <i>Brain Research</i> , 1994 , 637, 181-9	3.7	18
46	Botulinum toxin for chronic anal fissure. <i>Lancet, The</i> , 1994 , 344, 1127-8	40	156
45	Clinical usefulness of apomorphine in movement disorders. Clinical Neuropharmacology, 1994 , 17, 243-5	59.4	60
44	Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. <i>Neuroscience</i> , 1993 , 55, 823-32	3.9	49
43	Botulinum toxin as a treatment for blepharospasm, spasmodic torticollis and hemifacial spasm. <i>European Neurology</i> , 1992 , 32, 112-7	2.1	37
42	Chronic administration of MPTP to monkeys: behavioural morphological and biochemical correlates. <i>Neurochemistry International</i> , 1992 , 20 Suppl, 279S-285S	4.4	8
41	A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of L-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group. <i>Italian Journal of Neurological Sciences</i> , 1992 , 13, 735-9		9
40	Postural axial tremor in a patient with cerebellar atrophy. <i>Movement Disorders</i> , 1992 , 7, 273-80	7	9
39	Unsuspected, surreptitious drug-induced parkinsonism. <i>Neurology</i> , 1992 , 42, 459	6.5	4
38	Transient alternating hemichorea as presenting sign of progressive supranuclear palsy. <i>Italian Journal of Neurological Sciences</i> , 1991 , 12, 99-101		1
37	Correlation of cardiovascular autonomic function tests, magnetic resonance brain imaging and clinical features in suspect cases of multiple system atrophy. <i>Functional Neurology</i> , 1991 , 6, 269-73	2.2	2
36	Chronic Administration of 1-Methyl-4-Phenyl-1,2,3,6- Tetrahydropyridine to Marmosets. <i>Advances in Behavioral Biology</i> , 1991 , 523-531		1
35	Extrapyramidal system, motor Ganglia and movement disorders. <i>Reviews in the Neurosciences</i> , 1990 , 2, 145-64	4.7	7
34	Aging is associated with a diffuse impairment of forebrain cholinergic neurons. <i>Brain Research</i> , 1990 , 508, 51-9	3.7	108
33	Chronic administration of MPTP to marmosets. <i>Advances in Neurology</i> , 1990 , 53, 239-44		2
32	Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin. <i>Neuropharmacology</i> , 1989 , 28, 1089-97	5.5	42
31	Age-dependent loss of cholinergic neurones in basal ganglia of rats. <i>Brain Research</i> , 1988 , 455, 177-81	3.7	46
30	Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity. <i>Neuroscience Letters</i> , 1988 , 90, 100-6	3.3	27

(1981-1988)

29	Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <i>Neuroscience Letters</i> , 1988 , 87, 46-50	3.3	56
28	Can trazodone induce parkinsonism?. <i>Clinical Neuropharmacology</i> , 1988 , 11, 180-2	1.4	11
27	Suprasegmental control of vegetative nervous system. Functional Neurology, 1987, 2, 407-16	2.2	
26	A genetic study of neostriatal cholinergic neurones in C57BL/6 and DBA/2 mice. <i>Functional Neurology</i> , 1987 , 2, 273-9	2.2	5
25	Quantitative pharmacohistochemistry of acetylcholinesterase in neostriatum of inbred strains of mice. <i>Brain Research</i> , 1986 , 374, 402-8	3.7	12
24	Organization of central nervous system dopaminergic pathways. <i>Journal of Neural Transmission Supplementum</i> , 1986 , 22, 3-17		23
23	Histochemical demonstration of heavy metals in the reptilian archicortex. <i>International Journal of Neuroscience</i> , 1985 , 28, 11-9	2	6
22	Strain-dependent variations in the number of forebrain cholinergic neurons. <i>Brain Research</i> , 1985 , 334, 380-4	3.7	35
21	Cholinergic and non-cholinergic forebrain projections to the interpeduncular nucleus. <i>Brain Research</i> , 1985 , 329, 334-9	3.7	35
20	Neuropeptides in dopamine-containing regions of the brain. <i>Italian Journal of Neurological Sciences</i> , 1984 , 5, 391-404		3
19	Organization of the ascending projections from the ventral tegmental area: a multiple fluorescent retrograde tracer study in the rat. <i>Journal of Comparative Neurology</i> , 1983 , 216, 406-20	3.4	103
18	Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimers Presenile Dementia. <i>International Journal of Neuroscience</i> , 1983 , 18, 143-7	2	16
17	The organization of dopaminergic and non-dopaminergic mesencephalo-cortical neurons in the rat. <i>Brain Research</i> , 1982 , 238, 421-5	3.7	42
16	Retrograde fluorescent neuronal tracing combined with acetylcholinesterase histochemistry. <i>Journal of Neuroscience Methods</i> , 1982 , 6, 121-7	3	17
15	Peripheral neuropathy in the course of progressive systemic sclerosis: light and ultrastructural study. <i>Italian Journal of Neurological Sciences</i> , 1982 , 3, 341-8		15
14	The cortical projections of the thalamic intralaminar nuclei, as studied in cat and rat with the multiple fluorescent retrograde tracing technique. <i>Neuroscience Letters</i> , 1981 , 26, 5-10	3.3	79
13	Choline acetyltransferase (ChAT) activity differs in right and left human temporal lobes. <i>Neurology</i> , 1981 , 31, 799-805	6.5	99
12	Cholinergic-Monoaminergic Interactions in Selected Regions of the Brain: Histochemical and Pharmacologic Analyses. <i>Advances in Behavioral Biology</i> , 1981 , 723-738		3

11	Acetylcholinesterase and catecholamine distribution in the locus ceruleus of the rat. <i>Brain Research Bulletin</i> , 1980 , 5, 127-34	3.9	56	
10	Oligophrenia with the Hallermann-Streiff syndrome. <i>Journal of Neurology</i> , 1979 , 220, 211-4	5.5	5	
9	Locus ceruleus somata contain both acetylcholin esterase and norepinephrine: direct histochemical demonstration on the same tissue section. <i>Neuroscience Letters</i> , 1979 , 14, 101-4	3.3	40	
8	Management of sleep disorders in Parkinson's disease151-161		1	
7	Hyperkinesia, dystonia, and tics291-300			
6	Hypersalivation201-228			
5	Diagnosis and Treatment of Primary (Idiopathic) Dystonia191-206			
4	Other Jerks and Startles236-256			
3	Dyskinesias in Parkinsonian Syndromes297-310			
2	Distinguishing Clinical Features of Hyperkinetic Disorders1-14		3	
1	Primary Dystonias113-134		2	